Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are studying HIV prevention among women in Blantyre, Malawi, focusing on choices and preferences between long-acting injectable PrEP and oral PrEP. The study aims to understand the impact of rolling out injectable PrEP alongside oral PrEP by tracing women who have stopped or lost contact with PrEP services within the past two years. It also seeks to explore reasons for discontinuation, user experiences, and preferences for re-engagement. Participants include women who have missed their PrEP visits by three months or more and whose outcomes are unknown. The study involves two groups one receiving standard care per national guidelines with counseling and follow-up messages, and another receiving standard care plus a tracing strategy to determine their PrEP status. The tracing strategy includes phone calls and, with consent, in-person home visits to reconnect participants with care. Women traced will complete surveys assessing their HIV outcomes and preferences, and a subset will participate in interviews alongside healthcare providers to better understand PrEP use and discontinuation. Researchers will measure the number of women who return to PrEP after tracing and assess drug levels through dried blood samples. The study lasts about two years and aims to inform better strategies for maintaining PrEP use and preventing HIV among women in Malawi.
Actively Recruiting
Researchers are evaluating a device called BreathAlert, developed by Rice University in collaboration with clinicians at Queen Elizabeth Central Hospital, to monitor apnea in infants and children at risk. This observational study aims to assess BreathAlerts ability to detect respiration and apneic episodes by comparing its performance to traditional vital sign monitors, which include measurements such as temperature, heart rate, EKG, respiratory rate, SPO2, and impedance pneumography. During the study, the BreathAlert device, a low-cost battery-powered respiratory rate and apnea monitor, is attached to patients in the neonatal or pediatric ward who are at risk for apnea or require respiratory rate monitoring. Data is collected simultaneously from both BreathAlert and standard vital signs monitors while the patient is being observed. Participants will have the BreathAlert device attached while they are at risk for apnea, and researchers will collect data from both the device and existing monitors. The main outcome measured is the accuracy of BreathAlert over a maximum period of one week. The study involves patients from newborns up to 17 years old, with caregiver consent required, and continues until study completion in June 2028.
Actively Recruiting
Researchers are studying the use of different antibiotic treatments for newborns with all-risk asymptomatic congenital syphilis, a condition passed from mother to baby during pregnancy. This phase II study aims to evaluate the safety and how the body processes these antibiotics in newborns, comparing three different treatment options. The treatments being evaluated include a 10-day course of oral Linezolid given twice daily, a 10-day course of oral Amoxicillin given twice daily, and a single intramuscular injection of Benzathine Penicillin G. Participants are randomly assigned to one of these three treatment groups to compare their effects. During the study, newborns will be closely monitored from enrollment through 10 days of treatment, with assessments including blood and cerebrospinal fluid antibiotic levels and tracking any adverse events up to 24 weeks. Researchers will also evaluate clinical outcomes over this period. The total participation may last up to 24 weeks to ensure safety and effectiveness monitoring.
Actively Recruiting
Researchers are investigating why the impact of SARS-CoV-2 in sub-Saharan African countries, specifically Malawi, appears milder compared to Europe and the Americas. The study aims to understand how innate immune responses, malaria, intestinal parasites, undernutrition, and anemia influence infection risk, symptom progression, transmission, and responses to SARS-CoV-2 vaccination. They are assessing immune responses and vaccine effects in various groups to better understand susceptibility and immunity in this population. The study includes up to 200 symptomatic individuals confirmed with SARS-CoV-2 infection, their household contacts about 700, and up to 600 vaccine recipients aged 5 to 75 years. Participants undergo multiple visits for blood and stool sample collection over a follow-up period of up to 1.5 years. Vaccine recipients receive either the AstraZeneca or Johnson and Johnson vaccines, with samples collected at specific intervals after vaccination to monitor immune responses. Participants will have blood drawn at baseline and multiple follow-up visits to measure antibody levels, cellular immune responses, and markers of inflammation. Stool samples will be collected to diagnose intestinal parasites. Researchers will also monitor infection rates, symptom duration, and vaccine responses. The study will track these measures over time to assess how infections and vaccinations affect immunity and disease outcomes, with the overall participation lasting up to 15 months after initial enrollment.
Actively Recruiting
Researchers are evaluating the safety and effects of a single intravenous dose of 6-diazo-5-oxo-L-norleucine DON in healthy adults, adults with uncomplicated malaria, and children aged 12 months to 14 years with cerebral malaria. This study includes two parts an open-label dose escalation in adults and a randomized, placebo-controlled dose escalation in children with cerebral malaria, aiming to understand safety, pharmacokinetics, and potential effects on brain blood flow, brain volume, and brain activity patterns. In the first part, adult participants receive increasing doses of DON ranging from 0.1 to 10 mgkg intravenously, along with premedication using ondansetron to prevent nausea. Adults with uncomplicated malaria also receive standard antimalarial therapies. In the second part, children with cerebral malaria receive either DON at doses of 0.1 or 1.0 mgkg or placebo, alongside antimalarial treatments, across four cohorts with differing dose and randomization ratios. Pediatric participation spans three malaria seasons, with a total study duration of six months for both adults and children. Participants undergo safety evaluations including monitoring for adverse events and assessments of coma scores. Pharmacokinetic measurements of DON levels are taken up to 18 hours post-infusion. Children with cerebral malaria also have brain blood flow evaluated by transcranial Doppler, brain volume assessed by MRI, and brain activity recorded by EEG. Follow-up and safety monitoring continue for six months after dosing to assess the effects and tolerability of DON.
Actively Recruiting
Researchers are evaluating large language models LLMs as clinical decision support tools in healthcare settings of low and middle income countries. These settings often face challenges such as time pressure, limited diagnostic resources, and inconsistent access to current clinical guidelines. This observational study, part of the MOOVE project, aims to rigorously assess LLMs performance and safety compared to human clinical care in real-world acute condition cases. The study is non-interventional and conducted during routine outpatient care in participating facilities. Patient clinical and demographic data collected during visits are used to retrospectively prompt the LLMs without affecting patient treatment. The LLM outputs and human care plans are reviewed by independent clinical experts. Implementation feasibility is also assessed by gathering clinician feedback on the LLM interface, output clarity, relevance, safety perceptions, and alignment with clinical workflows and guidelines. Participants are followed up at 7 and 28 days after enrollment to collect clinical outcomes for evaluating LLM safety and performance. The study also monitors clinician experience and organizational readiness for future LLM implementation from week 4 until study completion. Outcome measures include performance scores at day 0 and safety thresholds at days 7 and 28, alongside ongoing implementation feasibility research. The total study duration extends through 2026.
Actively Recruiting
Researchers are investigating new treatment options for adults with newly diagnosed, drug-sensitive pulmonary tuberculosis through a phase 2BC open-label platform study. The trial compares several experimental drug regimens with a standard control treatment to assess efficacy and safety. Participants include adults aged 18 to 65 years with confirmed pulmonary tuberculosis sensitive to rifampicin and isoniazid. The study aims to optimize doses of existing drugs and introduce new medications to improve treatment outcomes. The study is divided into three stages. In stage 1, participants are randomly assigned to the control or one of two experimental arms containing high-dose rifampicin and other drugs for 12 to 17 weeks. Stage 2 adds an experimental arm including the drug BTZ-043, with participants allocated across four arms in varying ratios. Stage 3 begins after stages 1 and 2 complete enrollment, comparing the control arm with two new experimental arms involving novel drug combinations. Treatments are given once daily, with dosages adjusted by arm and weight. Participants will undergo sputum testing, chest X-rays, and molecular tests to confirm tuberculosis and drug sensitivity before enrollment. During the study, researchers will monitor participants through regular clinical assessments, laboratory tests, and electrocardiograms to track treatment response and safety. The main outcomes measured include time to stable culture conversion and changes in mycobacterial load. Safety is evaluated by recording adverse events and laboratory abnormalities over the treatment period, with follow-up continuing up to 12 months after randomization.
Actively Recruiting
Healthy Volunteer
Group B Streptococcus GBS is a leading cause of sepsis and bacterial meningitis in newborns during the first 90 days of life, contributing significantly to newborn deaths. Researchers are preparing for maternal GBS vaccine trials in Africa to improve infection prevention through better data collection, surveillance, and vaccine confidence. The PROTECT project supports sites in Kenya, Malawi, Mozambique, and Uganda to establish uniform pregnancy and infant health data, monitor GBS incidence, and understand factors affecting vaccine acceptance. The study consists of three main parts creating pregnancy exposure registries using electronic health records to track pregnancy and infant outcomes conducting a prospective observational GBS surveillance study among infants under 90 days with confirmed GBS infection at sentinel sites and assessing vaccine confidence through surveys and interviews with pregnant women, healthcare workers, and community leaders. These activities aim to strengthen healthcare systems for future vaccine trials and rollout. Participants include pregnant women and their infants up to hospital discharge for the registry infants under 90 days with confirmed GBS infection for surveillance and pregnant women, healthcare workers, and community stakeholders for vaccine confidence research. The study involves collecting and analyzing medical records, microbiological data, and survey responses over periods ranging from 12 months to two years. Researchers will monitor pregnancy and infant outcomes, GBS infection rates, and vaccine knowledge to prepare for vaccine safety monitoring and effective vaccine implementation.
Actively Recruiting
Healthy Volunteer
Skin pigmentation, skin phototype, and photodamage are important factors affecting skin cancer risk, appearance of skin diseases, treatment responses, and the accuracy of AI diagnosis in dermatology. However, current classification methods are often subjective and can lead to misclassification, reducing the precision of personalized care. This international multicenter observational study aims to develop and validate AI algorithms that classify these skin characteristics more accurately using a combination of objective measures and clinical assessments. Participants aged 18 years and older from multiple countries will complete questionnaires about their skin and sun exposure. Researchers will capture standardized clinical and dermoscopic images of the upper arm and forearm, and perform skin pigmentation measurements using techniques like colorimetry or spectrophotometry when available. The study combines data from questionnaires, objective measurements, clinical scales, and trained observers to create a reliable reference standard for skin pigmentation, phototype, and photodamage. These data will then be used to train and test deep learning AI models. Participants will provide non-invasive skin images and complete questionnaires without any invasive procedures or collection of personal identifiers. The study will assess how well the AI models classify skin characteristics compared to combined reference methods, focusing on accuracy and agreement measures. External validation will also be performed using independent dermatology image datasets to evaluate model performance across diverse populations. The study aims to improve personalized skin cancer risk assessment, support better dermatology care, and address biases in AI systems related to skin tone. Participation involves minimal risk and secure data handling.
Actively Recruiting
Researchers are evaluating the RTS,SAS01 malaria vaccine through case-control studies embedded within the Malaria Vaccine Pilot Evaluation MVPE conducted in Ghana, Malawi, and Kenya. This observational study aims to assess the vaccines safety with focus on cerebral malaria, meningitis, and severe malaria, as well as its impact on all-cause mortality among children aged 6 months to 59 months. The study also supports the use of case-control methods in immunization and malaria control programs. The study involves two main case-control components clinical outcomes and mortality outcomes. For clinical outcomes, children living in MVPE areas who meet case or control definitions based on hospital surveillance are recruited, with each case matched to four controls. The mortality component recruits children who died from any cause excluding accidents or trauma and matches them with four live controls. Data collection includes administering questionnaires to caregivers at their homes and gathering information from hospital and community surveillance systems. Participants will be involved through consented data collection via questionnaires and surveillance records. Data on meningitis, severe malaria, cerebral malaria, and mortality by gender are collected and analyzed. Controls are recruited by canvassing households near cases to match age and location. The study spans 45 months, with ongoing monitoring of outcomes including hospital admissions and deaths. Findings will support vaccine safety and effectiveness assessments and inform policy decisions.
1-10 of 14
1